Stockscreener 앱 받기
0.00
100.00%
-46.99
시간 외 거래:
46.98
46.98
+
전일 마감가:
$46.99
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$3.52B
수익:
-
순이익/손실:
$-275.16M
주가수익비율:
0.00
EPS:
-3.89
순현금흐름:
$-221.15M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
명칭
Springworks Therapeutics Inc
전화
203-883-9490
주소
100 WASHINGTON BOULEVARD, STAMFORD, CT
SWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
0.00 | 3.52B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-20 | 개시 | Evercore ISI | Outperform |
| 2024-02-05 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-03-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-04 | 개시 | H.C. Wainwright | Buy |
| 2019-10-08 | 개시 | Cowen | Outperform |
| 2019-10-08 | 개시 | Goldman | Buy |
| 2019-10-08 | 개시 | JP Morgan | Overweight |
| 2019-10-08 | 개시 | Wedbush | Outperform |
모두보기
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence - MSN
How volatile is SpringWorks Therapeutics Inc. stock compared to the marketEarnings Report Opportunities To Watch Now - jammulinksnews.com
What institutional investors are buying SpringWorks Therapeutics Inc. stockBeginner Investor Tips With Low Risk - jammulinksnews.com
Should I hold or sell SpringWorks Therapeutics Inc. stock in 2025Value Investing Data Feed For Beginners - jammulinksnews.com
What catalysts could drive SpringWorks Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - jammulinksnews.com
Published on: 2025-07-30 08:30:59 - metal.it
Published on: 2025-07-29 02:19:36 - beatles.ru
Sentiment Tools Show Shift in Trader Mood on SpringWorks Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
What makes SpringWorks Therapeutics Inc. stock price move sharplyEarly Breakout Entry Point Notifications Sent - metal.it
Is SpringWorks Therapeutics Inc. a growth stock or a value stockUnlock exclusive stock market forecasts - jammulinksnews.com
What are SpringWorks Therapeutics Inc. company’s key revenue driversAchieve breakthrough investment performance - jammulinksnews.com
Is SpringWorks Therapeutics Inc. stock overvalued or undervaluedFree Market Volatility Navigation Tips - jammulinksnews.com
Why SpringWorks Therapeutics Inc. stock attracts strong analyst attentionEarly Breakout Tracker - metal.it
What drives SpringWorks Therapeutics Inc. stock priceDynamic portfolio growth - Autocar Professional
Is SpringWorks Therapeutics Inc. a good long term investmentFree Market Volatility Navigation Tips - PrintWeekIndia
What analysts say about SpringWorks Therapeutics Inc. stockFree Investment Community - PrintWeekIndia
SpringWorks Therapeutics Inc. Stock Analysis and ForecastConsistent wealth multiplication - PrintWeekIndia
Neurofibromatosis Type 2 Pipeline 2025: MOA and ROA Insights, - openPR.com
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - MSN
European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients - Nasdaq
European Commission Grants Conditional Approval of EZMEKLY® - GlobeNewswire
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - Yahoo Finance
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know - Nasdaq
Principal Financial Group Inc. Decreases Stock Position in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
CIBRA Capital Ltd Purchases New Holdings in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics - Hartford Business Journal
Merck completes $3.4bn acquisition of SpringWorks Therapeutics - World Pharmaceutical Frontiers
Merck concludes SpringWorks acquisition for $3.4bn - Yahoo Finance
SpringWorks Therapeutics, Inc.(NasdaqGS: SWTX) dropped from S&P TMI Index - MarketScreener
SpringWorks Therapeutics Completes Merger and Delisting - TipRanks
SpringWorks Therapeutics: Unlocking Value Through Merck's EU Regulatory Milestones - AInvest
Springworks Therapeutics Inc (SWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.15%
자본화:
|
볼륨(24시간):